Glaucoma care is expanding beyond a simple choice between drops and filtration surgery. Nova Eye Medical develops glaucoma devices designed to support procedural intervention, informed by close collaboration with ophthalmic surgeons. Our portfolio includes the iTrack™ family for canaloplasty procedures and Molteno3® for severe and complex cases. We focus on platform technologies that can be adopted, taught and scaled across different clinical settings.
Nova Eye Medical works with ophthalmic surgeons, teaching institutions and research partners to guide product development and clinical education. Feedback continues after launch, informing refinements, training and supporting resources. The goal is practical fit across real workflows and real patient populations.
Nova Eye Medical maintains in-house manufacturing capability, supporting quality control, reliable supply and ongoing refinement. It also enables faster iteration when improvements are identified through surgeon feedback or training experience. For a regulated medical device business, the combination of consistency and agility matters. This is the US version
The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
INDICATIONS (USA): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.The ab interno surgical technique is not a cleared indication of the iTrack™ Advance in the USA.
*The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.
CONTRAINDICATIONS (USA): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.
PRECAUTIONS (USA): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
© 2026. Nova Eye, Inc. E&OE. Patents pending and/or granted. iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye, Inc.
The iTrack™ has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K080067 for the treatment of open-angle glaucoma.
INDICATIONS: The iTrack™ canaloplasty microcatheter is indicated for fluid infusion or aspiration during surgery. The iTrack™ canaloplasty microcatheter is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.The ab interno surgical technique is not a cleared indication for the iTrack™ in the USA.
CONTRAINDICATIONS: The iTrack™ canaloplasty microcatheter is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: neovascular glaucoma; angle closure glaucoma; and, previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS: Possible adverse events with the use of the iTrack™ canaloplasty microcatheter include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
WARNINGS: The iTrack™ canaloplasty microcatheter is intended for one time use only. DO NOT re-sterilize and/or reuse, as this can compromise device performance and increase the risk of cross contamination due to inappropriate reprocessing.
PRECAUTIONS: The iTrack™ canaloplasty microcatheter should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
The Molteno3® has has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #KK062252.
INDICATIONS: The Molteno3® Glaucoma Drainage Device is indicated to reduce intraocular pressure in neovascular glaucoma and glaucoma where medical and conventional surgical treatments have not been successful, to control the progression of disease.
CONTRAINDICATIONS: Patients with the following conditions may not be suitable candidates for the Molteno3® Glaucoma Drainage Device: 1. intraocular infection, 2. rheumatoid arthritis, scleritis and immune corneal melt syndromes, 3. Scleral Buckle.
COMPLICATIONS: Possible complications with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: choroidal detachment, retinal detachment, expulsive haemorrhage, pupillary block, lenticulo-ciliary block, shallowing and flattening of the anterior chamber, intraocular infection, diplopia, loss of central vision, hypotony and corneal endothelial damage.
Adverse Events: Possible adverse events with the use of the Molteno3® Glaucoma Drainage Device include, but are not limited to: corneal endothelial damage when the tube touches the corneal endothelium, breakdown of the tissues overlying the bleb, diplopia when the placement of the implant interferes with the action of the extraocular muscles, corneal decompensation, progression of lens opacities, cystoid macular oedema, retinal detachment and intraocular infection.
